ANG Lifesciences

Why is ANG Lifesciences India Ltd falling/rising?

As of 08-Aug, ANG Lifesciences India Ltd's stock price is rising to 32.65, indicating a potential shift in investor sentiment after a trend reversal. Increased investor participation and a price above long-term moving averages suggest a recovery phase, despite significant declines over the past few years.

As of 08-Aug, ANG Lifesciences India Ltd's stock price is rising, currently at 32.65, with a change of 0.48 (1.49%) upwards. This increase follows a trend reversal after four consecutive days of decline, indicating a potential shift in investor sentiment. Additionally, the stock has outperformed its sector by 1.37% today, suggesting stronger relative performance compared to peers.<BR><BR>Investor participation has notably increased, with delivery volume rising by 281.6% against the 5-day average, which reflects growing interest in the stock. Furthermore, the current price is higher than the 100-day and 200-day moving averages, although it remains lower than the 5-day, 20-day, and 50-day moving averages. This mixed moving average situation indicates that while the stock has seen recent gains, it may still be in a recovery phase after a longer-term decline, as evidenced by its performance over the past three and five years, where it has fallen significantly compared to the benchmark Sensex.<BR><BR>Overall, the combination of a price increase today, improved investor participation, and a trend reversal contributes to the stock's rising price.

Which are the latest news on ANG Lifesciences?

What does ANG Lifesciences do?

ANG Lifesciences India Ltd is a Micro Cap company in the Pharmaceuticals & Biotechnology sector, with recent net sales of 24 Cr and a net profit of -1 Cr as of March 2026. The company has a market cap of INR 39 Cr and operates from Amritsar, Punjab.

Overview: <BR>ANG Lifesciences India Ltd operates in the Pharmaceuticals & Biotechnology industry and is classified as a Micro Cap company.<BR><BR>History: <BR>The company was originally incorporated as a Private Limited Company on June 14, 2006. It converted to a Public Limited Company on March 02, 2010, and then reverted to a Private Limited Company on September 22, 2010. The latest quarterly results report net sales and profit for the period ending March 2026.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 24 Cr (Quarterly Results - Mar 2026) <BR>Most recent Net Profit: -1 Cr (Quarterly Results - Mar 2026) <BR>Market-cap value: INR 39 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: N/A <BR>Industry P/E: 34 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 1.43 <BR>Return on Equity: -20.97% <BR>Price to Book: 0.74<BR><BR>Contact Details: <BR>Address: Darbara Complex SCO 113 I Flr, Dist. Shopping Centre B Block Amritsar Punjab : 143001 <BR>Tel: 91-0183-5070118/5070119 <BR>Email: cs@anglifesciences.com <BR>Website: http://www.anglifesciences.com

How big is ANG Lifesciences?

As of 10th June, ANG Lifesciences India Ltd has a market capitalization of 39.00 Cr and reported net sales of 92.88 Cr with a net loss of 11.09 Cr over the latest four quarters. Shareholder's funds are 63.98 Cr, and total assets amount to 223.22 Cr as of March 2025.

As of 10th June, <BR><BR>Market Cap: ANG Lifesciences India Ltd has a market capitalization of 39.00 Cr, classified as a Micro Cap.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 92.88 Cr, while the sum of Net Profit for the same period reflects a loss of 11.09 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the latest annual data is March 2025. Shareholder's Funds stand at 63.98 Cr, and Total Assets amount to 223.22 Cr.

Who are in the management team of ANG Lifesciences?

The management team of ANG Lifesciences includes Rajesh Gupta (Managing Director), Saruchi Gupta (Whole Time Director & CFO), Sukhpal Singh, Pawanjit Singh, and Chetna (Independent Directors), Sudesh Kumari (Director), and Renu (Company Secretary & Compliance Officer).

The management team of ANG Lifesciences includes the following individuals:<BR><BR>1. **Rajesh Gupta** - Managing Director<BR>2. **Saruchi Gupta** - Whole Time Director & CFO<BR>3. **Sukhpal Singh** - Independent Director<BR>4. **Sudesh Kumari** - Director<BR>5. **Pawanjit Singh** - Independent Director<BR>6. **Chetna** - Independent Director<BR>7. **Renu** - Company Secretary & Compliance Officer<BR><BR>If you need more details about any specific member or their roles, feel free to ask!

Who are the peers of the ANG Lifesciences?

Peers of ANG Lifesciences include Mangalam Drugs, Vista Pharma, Rajnish Wellness, Sandu Pharma, Murae Organisor, Lasa Supergeneri, Roopa Industries, Medi Caps, and Welcure Drugs. ANG Lifesciences has a 1-year return of -7.18%, outperforming peers like Sandu Pharma (-21.83%) and Murae Organisor (-83.76%).

Peers: The peers of ANG Lifesciences are Mangalam Drugs, Vista Pharma., Rajnish Wellness, Sandu Pharma., Murae Organisor, Lasa Supergeneri, Roopa Industries, Medi Caps, and Welcure Drugs.<BR><BR>Quality Snapshot: Below Average management risk is observed at Mangalam Drugs, Vista Pharma., Rajnish Wellness, Sandu Pharma., Murae Organisor, Lasa Supergeneri, Roopa Industries, Medi Caps, and ANG Lifesciences, while Average management risk is found at Welcure Drugs. Below Average growth is noted for Mangalam Drugs, Vista Pharma., Rajnish Wellness, Lasa Supergeneri, and the rest, while Good growth is seen at Murae Organisor and Roopa Industries. Capital Structure ratings show Good at Sandu Pharma. and Medi Caps, Average at Lasa Supergeneri, and Below Average at the rest.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Sandu Pharma. at -21.83%, while the peer with the lowest is Murae Organisor at -83.76%. ANG Lifesciences has a 1-year return of -7.18%, which is better than both of these peers. Additionally, peers such as Rajnish Wellness, Murae Organisor, Lasa Supergeneri, Roopa Industries, Medi Caps, and Welcure Drugs have negative six-month returns.

Should I buy, sell or hold ANG Lifesciences India Ltd?

Are ANG Lifesciences India Ltd latest results good or bad?

ANG Lifesciences India Ltd's latest results show a 39.71% revenue growth and improved operating margins, but the company still reported a net loss of ₹1.38 crores and negative return on equity, indicating ongoing profitability challenges despite some operational improvements.

ANG Lifesciences India Ltd's latest results present a mixed picture. On one hand, the company achieved a significant revenue growth of 39.71% year-on-year, with net sales reaching ₹23.50 crores, which is a positive indicator of demand recovery. Additionally, the operating margin improved to 11.36%, marking the highest level in eight quarters, reflecting better cost management.<BR><BR>However, despite these improvements, the company reported a net loss of ₹1.38 crores for Q1 FY27, which, while down 70.95% from the previous quarter's loss, still indicates ongoing profitability challenges. The return on equity remains negative at -20.69%, suggesting that the company is not generating value for shareholders. <BR><BR>Overall, while there are signs of operational improvement, the persistent losses and negative profitability metrics highlight significant underlying issues that could overshadow the positive revenue growth. Thus, the results can be seen as a cautious improvement rather than a definitive turnaround.

When is the next results date for ANG Lifesciences India Ltd?

ANG Lifesciences India Ltd will announce its results on 14 February 2026.

ANG Lifesciences India Ltd is scheduled to declare its results on 14 February 2026.

How has been the historical performance of ANG Lifesciences?

ANG Lifesciences has experienced a significant decline in net sales and profitability, with net sales dropping from INR 354.30 crore in March 2022 to INR 92.85 crore in March 2025, and profit after tax turning from a profit of INR 40.32 crore to a loss of INR 12.41 crore in the same period. The company's total assets and liabilities also decreased, and cash flow from operating activities fell to zero in March 2025.

Answer:<BR>The historical performance of ANG Lifesciences shows a significant decline in net sales and profitability over the past few years.<BR><BR>Breakdown:<BR>ANG Lifesciences experienced a decrease in net sales from INR 354.30 crore in March 2022 to INR 92.85 crore in March 2025. This downward trend is mirrored in total operating income, which fell from INR 354.30 crore in March 2022 to the same INR 92.85 crore in March 2025. The company's operating profit (PBDIT) also declined sharply, moving from a profit of INR 68.28 crore in March 2022 to a loss of INR 0.25 crore in March 2025. Profit before tax followed a similar trajectory, dropping from INR 53.50 crore in March 2022 to a loss of INR 15.70 crore in March 2025. Consequently, profit after tax also turned negative, going from a profit of INR 40.32 crore in March 2022 to a loss of INR 12.41 crore in March 2025. The company's total assets decreased from INR 286.75 crore in March 2022 to INR 223.22 crore in March 2025, while total liabilities also saw a reduction from INR 286.75 crore to INR 223.22 crore in the same period. Cash flow from operating activities has fluctuated, with a notable drop to zero in March 2025, compared to INR 26 crore in March 2023. Overall, ANG Lifesciences has faced significant challenges, reflected in its declining sales, profits, and cash flow over the years.

Who are the top shareholders of the ANG Lifesciences?

The top shareholders of ANG Lifesciences include promoters, with Rajesh Gupta holding 70.41% of the shares, while individual investors own 26.11%. There are no mutual funds or foreign institutional investors currently involved.

The top shareholders of ANG Lifesciences are primarily the promoters, with Rajesh Gupta holding the highest stake at 70.41%. Additionally, individual investors collectively own 26.11% of the company. There are currently no mutual funds or foreign institutional investors (FIIs) holding shares in ANG Lifesciences.

Is ANG Lifesciences overvalued or undervalued?

As of August 16, 2024, ANG Lifesciences is considered risky and overvalued due to its negative PE ratio of -3.13, EV to EBITDA of -51.95, and poor financial performance, including a 41.32% decline in stock value over the past year compared to the Sensex's gain of 7.59%.

As of 16 August 2024, the valuation grade for ANG Lifesciences has moved from very attractive to risky, indicating a significant shift in its perceived value. The company appears to be overvalued based on its current metrics, with a PE ratio of -3.13, an EV to EBITDA of -51.95, and a ROE of -19.40%. These figures suggest that the company is struggling financially, which is further reflected in its negative returns over the past year and three years.<BR><BR>In comparison to its peers, ANG Lifesciences stands out with its negative PE ratio and EV to EBITDA, while other companies in the pharmaceuticals and biotechnology sector maintain positive valuations. For instance, if we consider a typical peer with a PE ratio around 15 and a more favorable EV to EBITDA, ANG Lifesciences clearly lags behind. Additionally, the stock has underperformed against the Sensex over the past year, with a decline of 41.32% compared to the index's gain of 7.59%. This reinforces the conclusion that ANG Lifesciences is currently overvalued.

What is the technical trend for ANG Lifesciences?

As of May 19, 2025, ANG Lifesciences shows a mildly bearish trend overall, with mixed signals from indicators like the weekly MACD being mildly bullish and daily moving averages indicating short-term weakness.

As of 19 May 2025, the technical trend for ANG Lifesciences has changed from bearish to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the monthly MACD also shows mildly bullish. However, the daily moving averages are mildly bearish, suggesting short-term weakness. The Bollinger Bands on both weekly and monthly time frames are mildly bearish, reinforcing the cautious outlook. The KST is mildly bullish on the weekly but bearish on the monthly, indicating mixed signals. Overall, the current technical stance is mildly bearish, with key indicators such as the daily moving averages and Bollinger Bands driving this assessment.

What is the bonus history of the ANG Lifesciences?

ANG Lifesciences has issued bonuses in recent years, including a 1:4 bonus on July 13, 2022, and a 1:1 bonus on September 22, 2021, reflecting a commitment to rewarding shareholders.

ANG Lifesciences has a notable bonus history. The most recent bonus issue was a 1:4 bonus announced on July 13, 2022, with a record date of July 14, 2022. Prior to that, the company issued a 1:1 bonus on September 22, 2021, with a record date of September 23, 2021. This indicates a pattern of rewarding shareholders through bonus shares in recent years.

Has ANG Lifesciences declared dividend?

ANG Lifesciences India Ltd has declared a 10% dividend, amounting to ₹1 per share, with an ex-date of November 2, 2021. However, the total returns over various periods show significant losses, and the dividend yield remains at 0%.

ANG Lifesciences India Ltd has declared a 10% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 10%<BR>- Amount per share: 1 per share<BR>- Ex-date: 02 Nov 21<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -36.53%, the dividend return was 0%, resulting in a total return of -36.53%.<BR><BR>Over the past year, the price return was -43.38%, with a dividend return of 0%, leading to a total return of -43.38%.<BR><BR>In the 2-year period, the price return was -59.24%, the dividend return was 0%, culminating in a total return of -59.24%.<BR><BR>For the 3-year period, the price return was -83.81%, with a dividend return of 0%, resulting in a total return of -83.81%.<BR><BR>In the 4-year period, the price return was -56.25%, the dividend return was 1.51%, leading to a total return of -54.74%.<BR><BR>Over the last 5 years, the price return was 92.43%, the dividend return was 6.12%, resulting in a total return of 98.55%.<BR><BR>Overall, while ANG Lifesciences has declared a dividend, the total returns over various periods indicate significant losses, particularly in the shorter time frames, with a positive return only in the 5-year period. The dividend yield remains at 0%, suggesting limited income generation from dividends in the recent past.